AGL Stock Analysis: agilon health | NYSE

Medical Care Facilities | NYSE, USA | Market Cap: 1.522m USD | 12M Return: 333.4% | US00857U2069 | Charts, Fundamentals & Technical Analysis

Senior Primary Care, Physician Enablement, Medicare Advantage, Population Health
Total Rating 43
Safety 34
Buy Signal 0.16
Medical Care Facilities
Industry Rotation: +0.1
Market Cap: 1.52B
Avg Turnover: 15.9M
Risk 3d forecast
Volatility87.0%
VaR 5th Pctl13.3%
VaR vs Median-5.55%
Reward TTM
Sharpe Ratio1.51
Rel. Str. IBD99.7
Rel. Str. Peer Group98.3 pctl
Character TTM
Beta2.157
Beta Downside-0.122
Hurst Exponent0.647
Choppyness44.9%
Drawdowns 3y
Max DD97.69%
CAGR/Max DD-0.38
CAGR/Mean DD-0.50
EPS (Earnings per Share) EPS (Earnings per Share) of AGL over the last years for every Quarter: "2021-09": -2.3, "2021-12": -0.14, "2022-03": 0.47, "2022-06": 0.19, "2022-09": -0.58, "2022-12": -0.14, "2023-03": 0.95, "2023-06": -1, "2023-09": -2, "2023-12": -0.41, "2024-03": -0.16, "2024-06": -1.81, "2024-09": -6.98, "2024-12": -0.25, "2025-03": 0.75, "2025-06": -6.3, "2025-09": -6.75, "2025-12": -0.358, "2026-03": 1.14, "2026-06": 1.04,
Last SUE: 0.46
Qual. Beats: 0
Revenue Revenue of AGL over the last years for every Quarter: 2021-09: 458.613, 2021-12: 462.886, 2022-03: 653.445, 2022-06: 670.134, 2022-09: 694.858, 2022-12: 689.774, 2023-03: 1054.312, 2023-06: 1069.115, 2023-09: 1136.863, 2023-12: 815.504, 2024-03: 1604.354, 2024-06: 1482.758, 2024-09: 1450.932, 2024-12: 1522.486, 2025-03: 1532.782, 2025-06: 1394.982, 2025-09: 1435.321, 2025-12: 1569.491, 2026-03: 1420.46, 2026-06: 1494.743,
Rev. CAGR: 15.75%
Rev. Trend: 84.8%
Last SUE: 0.72
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader
Idiosyncratic Leader

Seasonality 5.5 years of data

Jan +30.1% 24
Feb -3.2% 21
Mar +4.4% 0
Apr -2.5% 10
May +14.0% 10
Jun +9.2% 29
Jul +4.5% 27
Aug -17.2% 30
Sep -2.9% 11
Oct -16.9% 24
Nov -18.0% 49
Dec +6.7% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: AGL agilon health

Agilon health, Inc. provides healthcare services to seniors through community-based primary care physicians in the United States. Its platform manages patients’ overall healthcare needs using a subscription-like per-member-per-month payment model. Founded in 2016, the company is based in Westerville, Ohio.

Headlines to Watch Out For
  • Medicare Advantage membership growth lifts recurring per-member revenue
  • Rising medical costs pressure margins and cash flow
  • CMS payment and risk-adjustment changes reshape capitation economics
Piotroski VR-10 (Strict) 2.0
Net Income: -251.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.07 > 0.02 and ΔFCF/TA -2.94 > 1.0
NWC/Revenue: 1.79% < 20% (prev 3.45%; Δ -1.66% < -1%)
CFO/TA -0.05 > 3% & CFO -72.3m > Net Income -251.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.08 > 1.5 & < 3
Outstanding Shares: last quarter (17.2m) vs 12m ago 3.98% < -2%
Gross Margin: 0.00% > 18% (prev -1.76%; Δ 1.77% > 0.5%)
Asset Turnover: 358.3% > 50% (prev 344.5%; Δ 13.81% > 0%)
Interest Coverage Ratio: -37.58 > 6 (EBIT TTM -262.1m / Interest Expense TTM 6.97m)
Altman Z'' -4.37
A: 0.07 (Total Current Assets 1.42b - Total Current Liabilities 1.31b) / Total Assets 1.59b
B: -1.20 (Retained Earnings -1.91b / Total Assets 1.59b)
C: -0.16 (EBIT TTM -262.1m / Avg Total Assets 1.65b)
D: 0.17 (Book Value of Equity 227.5m / Total Liabilities 1.36b)
Altman-Z'' = -4.37 = D
Beneish M -3.21
DSRI: 1.01 (Receivables 1.06b/1.05b, Revenue 5.92b/5.90b)
GMI: 1.00 (fallback, negative margins)
AQI: 0.69 (AQ_t 0.09 / AQ_t-1 0.13)
SGI: 1.00 (Revenue 5.92b / 5.90b)
TATA: -0.11 (NI -251.2m - CFO -72.3m) / TA 1.59b)
Beneish M = -3.21 (Cap -4..+1) = AA
What is the price of AGL shares?

As of November 04, 2026, the stock is trading at USD 87.79 with a total of 329,698 shares traded. Over the past week, the price has changed by -3.15%, over one month by +4.16%, over three months by -6.72% and over the past year by +333.37%.

Current recommended Stop Loss: 81.90 (which is 6.7% or 1.2 ATR below the current price).

Is AGL a buy, sell or hold?

agilon health has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold AGL.

  • StrongBuy: 5
  • Buy: 0
  • Hold: 9
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the AGL price?
Analysts Target Price 115.8 31.9%
agilon health (AGL) - Fundamental Data Overview as of 29 October 2026
Market Cap USD = 1.52b (1.52b USD * 1.0 USD.USD)
P/E Forward = 178.5714
P/S = 0.2571
P/B = 6.667
Revenue TTM = 5.92b USD
EBIT TTM = -262.1m USD
EBITDA TTM = -234.0m USD
Long Term Debt = 15.4m USD (from longTermDebt, last quarter)
Short Term Debt = 14.9m USD (from shortTermDebt, last quarter)
Debt = 36.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.15m
Net Debt = -149.0m USD (calculated: Debt 36.6m - CCE 185.6m)
Enterprise Value = 1.37b USD (1.52b + Debt 36.6m - CCE 185.6m)
Interest Coverage Ratio = -37.58 (Ebit TTM -262.1m / Interest Expense TTM 6.97m)
EV/FCF = -12.22x (Enterprise Value 1.37b / FCF TTM -112.4m)
FCF Yield = -8.18% (FCF TTM -112.4m / Enterprise Value 1.37b)
FCF Margin = -1.90% (FCF TTM -112.4m / Revenue TTM 5.92b)
Net Margin = -4.24% (Net Income TTM -251.2m / Revenue TTM 5.92b)
Gross Margin = 0.00% ((Revenue TTM 5.92b - Cost of Revenue TTM 5.92b) / Revenue TTM)
Gross Margin QoQ = 7.17% (prev 4.10%)
Tobins Q-Ratio = 0.86 (Enterprise Value 1.37b / Total Assets 1.59b)
Interest Expense / Debt = 19.05% (Interest Expense 6.97m / Debt 36.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -207.0m (EBIT -262.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.08 (Total Current Assets 1.42b / Total Current Liabilities 1.31b)
Debt / Equity = 0.16 (Debt 36.6m / totalStockholderEquity, last quarter 227.5m)
 Debt / EBITDA = 0.64 (negative EBITDA) (Net Debt -149.0m / EBITDA -234.0m)
 Debt / FCF = 1.33 (negative FCF - burning cash) (Net Debt -149.0m / FCF TTM -112.4m)
 Total Stockholder Equity = 210.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.20% (Net Income -251.2m / Total Assets 1.59b)
RoE = -119.3% (Net Income TTM -251.2m / Total Stockholder Equity 210.4m)
 RoCE = -116.0% (out of range, set to none) (EBIT -262.1m / Capital Employed (Equity 210.4m + L.T.Debt 15.4m))
 RoIC = -191.2% (out of range, set to none) (NOPAT -207.0m / Invested Capital 108.3m)
 WACC = 12.93% (E(1.52b)/V(1.56b) * Re(12.88%) + D(36.6m)/V(1.56b) * Rd(19.05%) * (1-Tc(0.21)))
Discount Rate = 12.88% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 78.62 | Cagr: 2.29%
 [DCF] Fair Price = unknown (Cash Flow -112.4m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.46 | # QB: 0
Revenue Correlation: 84.84 | Revenue CAGR: 15.75% | SUE: 0.72 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.73 | Chg30d=+3.18% | Revisions=-22% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.79 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+92.5% | GrowthRev=-1.8%
EPS next Year (2027-12-31): EPS=2.36 | Chg30d=-1.67% | Revisions=+0% | GrowthEPS=+1591.5% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: -15% (up=4, down=6)